Moberg Pharma AB (publ) (STO:MOB)

Revenue by Segment

Financials in millions SEK. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2020	FY 2019	FY 2018	FY 2017
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Jun 30, 2020	Jun 30, 2019	Dec 31, 2018	Dec 31, 2017
Commercialization and Development of Medical Products	13.54M	9.81M		207.00K		33.66M	50.49M
Commercialization and Development of Medical Products Growth	37.99%	-		-		-33.33%	62.30%
Total	13.54M	9.81M		207.00K		33.66M	50.49M
Total Growth	37.99%	-		-		-33.33%	62.30%

Revenue by Geography

Financials in millions SEK. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2020	FY 2019	FY 2018	FY 2017
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Jun 30, 2020	Jun 30, 2019	Dec 31, 2018	Dec 31, 2017
Europe	13.54M	9.81M		-		-	-
Europe Growth	37.99%	-		-		-	-
Rest of The World	-	-		207.00K		33.66M	-
Total	13.54M	9.81M		207.00K		33.66M	-
Total Growth	37.99%	-		-		-	-

Data Source: S&P Global Market Intelligence Last updated: Mar 31, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Jul 3, 2026

Data Sources Report a data error